{'fraction_non_alphanumeric': 0.021628498727735368, 'fraction_numerical': 0.015267175572519083, 'mean_word_length': 4.847583643122676, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Antigen specific immune response to SARS-CoV-2 vaccines

Specific antibody and cellular response to SARS-CoV-2 vaccines has not been sufficiently mapped yet. Hungarian healthcare workers are largely exposed to the SARS-CoV-2 pandemic. Our aim was to investigate the specific immune response to mRNA vaccine (Pfizer) and its change over time in a sample of health care workers. We also aimed to examine the role of age in this process. For implementation 55 volunteer health workers were included in the study. Specific antibody tests were used to examine immunogenicity at 10 days and 2 months after the second dose of mRNA vaccine. Generic Assay IgG + test measures specific IgG against Spike1 and 2 proteins and nucleocapsid specific antibodies. The Roche Elecsys® Anti-SARS-CoV-2 S is an immunoassay for the quantitative determination of antibodies to the receptor binding domain. Ten days after the second dose all subjects showed a significant antibody production by both tests. The older age group responded with lower antibody levels (geometric means were 1915 and 1205 BAU/mL measured by Roche test in age groups below 55 years and after 55 years of age, respectively). Two months after the second dose, there was a significant decrease in antibody levels in both age groups. The decline is expected to continue, therefore the measurement will be repeated for another 3 months. Furthermore, we consider it necessary to supplement the study with cellular immunoassays. Preliminary results on these additional measurements will also be discussed in the presentation.